Coordination and Collaboration Sample Clauses

Coordination and Collaboration. As necessary, Service Provider shall coordinate and cooperate with other Service Providers contracted with the Authority, and other public interest and specialized focus groups, to enhance Covered Services and Member care generally. Service Provider shall also work with community-based organizations to meet the following outcomes for Members in the community: (i) the Member has access to the appropriate level of care; (ii) the Member and their family, when appropriate and authorized, are involved in the planning and provision of services and (iii) the services are individualized to meet each Member’s treatment needs while allowing the Member to remain at home or close to home in the least restrictive environment possible. Appropriate releases of information will be completed upon initiation of Service Provider’s Covered Services to the Member The provider identified as the CRSP for Covered Services shall ensure the coordination of care occurs between the Member’s Primary Care Physician and Medicaid Health Plan. Coordination of care is also required with any other health care providers, agencies, natural or community support as specified in the Member’s IPOS.
Sample 1Sample 2
AutoNDA by SimpleDocs
Coordination and Collaboration. The Project is exploring further opportunities to have coordination with current initiatives of USAID and other donor agencies in the sub-sector to achieve synergies. Agribusiness project is also coordinating with government agencies and departments for seeking policy leverage and awareness creation. The project is also building on the earlier initiatives such as FIRMS project and other initiatives funded by USAID. Consolidated Output based Activities and Progress Benchmarks during the Second Year’s Implementation of The Agribusiness Project Objective Out-Put based Activities Progress Benchmarks Objective-1 (S-IR 1.1.1): Strengthened Market Linkages in Selected Value Chains 1. Technical Assistance and Capacity Building Support under Export, Quality Assurance and Food- Safety Compliance Certifications 30 compliance certification facilitated.  Compliance ensured by 30 enterprises for compliance to standards.
Sample 1
Coordination and Collaboration. Utilizing the elements below, county emergency management agencies will have an ongoing process that provides for coordinated and collaborated input in the preparation, implementation, evaluation and revision of emergency management programs.  Attend the Regional Training and Exercise Planning (TEP) Workshop and provide an agenda or a copy of the certificate to show participation during this contract period (July 1, 2015 – June 30, 2016);  Attend the Private Sector Summit OR the Rural County Summit
Sample 1
Coordination and Collaboration. The Organiser shall coordinate the performance of the Exhibitor and their (sub)contractors and the collaboration between this Exhibitor and their (sub)contractors and their Facility when executing measures to ensure the well-being of staff when carrying out their work.
Sample 1
Coordination and Collaboration. The State shall coordinate activities de- scribed in paragraph (2) and this para- graph, among public and private entities that are responsible for policies, proce- dures, or funding for the provision of assis- tive technology devices and assistive tech- nology services to individuals with disabil- ities, service providers, and others to im- prove access to assistive technology de- vices and assistive technology services for individuals with disabilities of all ages in the State.
Sample 1
Coordination and Collaboration. The Project will explore opportunities to have coordination with current initiatives of USAID and other donor agencies in the sub-sector to achieve synergies. Coordination will also be in place with government agencies and departments for seeking policy leverage and awareness creation. The project will also build on the earlier initiative such as FIRMS project and other initiatives funded by USAID in the past. Table 7: Out-Put Based Activities and Performance Benchmarks under Monitoring and Evaluation Out-Put Based Activities Benchmarks for Measuring Achievements
Sample 1
Coordination and Collaboration. 7.4.1. Contractor shall coordinate with the following programs and coalitions to meet stakeholders, share best-practices, report on progress, and ensure the program does not duplicate services: San Diego County Childhood Obesity Initiative (COI)’s Schools & After-Schools Domain, and San Diego Unified School District Wellness Council, and report activities in the MPR.
Sample 1
AutoNDA by SimpleDocs
Coordination and Collaboration. In order to develop potential joint enforcement and implementation initiatives, increase efficiency, ensure coordination, and minimize duplication, DOJ FCS and HHS OCR will undertake:
Sample 1

Related to Coordination and Collaboration

  • Cooperation and Coordination The Parties acknowledge and agree that it is their mutual objective and intent to minimize, to the extent feasible and legal, taxes payable with respect to their collaborative efforts under this Agreement and that they shall use all commercially reasonable efforts to cooperate and coordinate with each other to achieve such objective.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development Services During the term of this Agreement, the Provider agrees to provide to or on behalf of the Port the professional services and related items described in Exhibit A (collectively, the “Development Services”) in accordance with the terms and conditions of this Agreement. The Provider specifically agrees to include at least one Port representative in any economic development negotiations or discussions in which the Provider is involved concerning (i) a port-related business prospect or (ii) a business transaction which will ultimately require Port involvement, financial or otherwise.

Time is Money Join Law Insider Premium to draft better contracts faster.